Peregrine Pharma (PPHM) recently announced that the US. Food and Drug Administration (FDA) has approved on the design for their Phase III registration trial for its oncology drug, Bavituximab.
A unique drug is on the right pathway to success, as Oncolytics Biotechnology (ONCY) is pushing Reolysin through the pipeline. David Williamson from Motley Fool reported that this cancer medication is based off a common virus, incidentally referred to as the new “Cancer-Killing Virus.”
AVEO Pharmaceuticals’ (AVEO) New Drug Application (NDA) with the FDA for their newly developed once a day oral medication to fight advanced renal cell carcinoma – known as Tivozanib – has hit a snag.Upon review, the FDA’s Oncologic Drugs Advisory Committee voted 13-1 against approval due to safety concerns.